外用薬CDMOの世界市場

外用薬CDMOの世界市場は2030年までに797億米ドルに到達

2024年に449億米ドルと推定される外用薬CDMOの世界市場は、2024年から2030年にかけてCAGR 10.0%で成長し、2030年には797億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである半固形製剤は、CAGR 8.4%を記録し、分析期間終了時には308億米ドルに達すると予測されます。液体製剤医薬品セグメントの成長率は、分析期間中CAGR 12.1%と推定されます。

米国市場は122億米ドルと推定、中国はCAGR13.4%で成長予測

米国の外用薬CDMO市場は2024年に122億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに160億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.4％と8.7％と予測されています。欧州では、ドイツがCAGR 7.8%で成長すると予測されています。

外用薬CDMO市場動向と促進要因のまとめ

CDMOは医薬品開発の情勢にどのような革命をもたらしているか？

CDMO（医薬品開発・製造受託機関）は、製剤開発から商業規模での生産まで、エンドツーエンドのサービスを提供することで、成長する外用薬市場で重要な役割を果たしています。皮膚科、疼痛管理、経皮薬物送達における外用薬の需要の増加が、ゲル、クリーム、ローション、軟膏、パッチを専門とするCDMOの拡大に拍車をかけています。生物製剤や新しいドラッグデリバリー技術の台頭は市場の可能性をさらに高めており、製薬会社はコスト削減と市場投入までの時間短縮のため、研究開発や製造をCDMOに委託しています。しかし、規制の複雑さ、サプライチェーンの課題、特殊な外用製剤の高コストなどは依然として大きなハードルとなっています。製薬企業が効率性と柔軟性を優先する中、CDMOは外用薬分野でどのようにイノベーションを推進し続けるのだろうか。

どのような技術革新が外用薬CDMOの能力を前進させているのか？

マイクロカプセル化とナノ粒子ベースのドラッグデリバリーの進歩により、外用剤の有効性と安定性が向上しています。AIを活用した予測モデリングは製剤開発を最適化し、初期段階の試験における時間とコストを削減しています。経皮マイクロニードルパッチは、非侵襲的なドラッグデリバリーの選択肢として台頭しており、CDMOの能力を従来のクリームや軟膏以上に拡大しています。連続処理やリアルタイムの品質管理分析を含むスマート製造技術は、生産効率を高めています。さらに、バイオ医薬品の進歩により、外用療法にペプチドやタンパク質を組み込むことが可能になり、慢性皮膚疾患や疼痛管理の治療選択肢が広がっています。

なぜ外用薬CDMOの需要が増加しているのか？

皮膚疾患の有病率の上昇、非侵襲的な薬物投与への嗜好の高まり、経皮ドラッグデリバリーシステムに対する需要の高まりが、専門的なCDMOの必要性を高めています。製薬会社は、インフラコストを削減し、厳しい規制要件を乗り切るために、開発と製造のアウトソーシングをますます進めています。個別化医療とカスタマイズされた局所療法の出現は、柔軟なCDMOパートナーシップの需要をさらに促進しています。

外用薬CDMO市場の成長を促す要因は何か？

ドラッグデリバリー技術の進歩、医薬品製造のアウトソーシングの増加、皮膚科治療や経皮療法の需要増加、バイオ医薬品製剤におけるCDMO能力の拡大が市場の成長をもたらしています。世界の製薬業界が受託製造を受け入れ続ける中、外用薬に特化したCDMOは、製薬会社に革新的で費用対効果の高いソリューションを提供し、大きな成長を遂げようとしています。

セグメント

製品タイプ（半固形製剤、液体製剤、固形製剤、経皮吸収型製剤）、サービスタイプ（受託開発、受託製造）、エンドユーザー（製薬会社、バイオ製薬会社、その他）

調査対象企業の例

• AbbVie Contract Manufacturing
• Acino
• Adare Pharma Solutions
• Alcami Corporation
• Ascendia Pharmaceuticals
• Aurobindo Pharma
• Avara Pharmaceutical Services
• Avid Bioservices
• Bora Pharmaceuticals
• Cambrex Corporation
• Catalent, Inc.
• CordenPharma
• DPT Laboratories Ltd.
• Famar
• Jubilant HollisterStier
• Kindeva Drug Delivery
• Lubrizol Life Science
• MedPharm Ltd.
• Patheon（Thermo Fisher Scientific）
• PCI Pharma Services
• Pierre Fabre Group
• Piramal Pharma Solutions

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Topical Drugs CDMO Market to Reach US$79.7 Billion by 2030

The global market for Topical Drugs CDMO estimated at US$44.9 Billion in the year 2024, is expected to reach US$79.7 Billion by 2030, growing at a CAGR of 10.0% over the analysis period 2024-2030. Semi-solid Formulations, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$30.8 Billion by the end of the analysis period. Growth in the Liquid Formulations Drugs segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.2 Billion While China is Forecast to Grow at 13.4% CAGR

The Topical Drugs CDMO market in the U.S. is estimated at US$12.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.4% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Topical Drugs CDMO Market Trends & Drivers Summarized

How Are CDMOs Revolutionizing the Topical Drug Development Landscape?

Contract Development and Manufacturing Organizations (CDMOs) are playing a crucial role in the growing topical drug market by offering end-to-end services, from formulation development to commercial-scale production. The increasing demand for topical drugs in dermatology, pain management, and transdermal drug delivery is fueling the expansion of CDMOs specializing in gels, creams, lotions, ointments, and patches. The rise of biologics and novel drug delivery technologies is further enhancing market potential, with pharmaceutical companies outsourcing R&D and manufacturing to CDMOs to reduce costs and accelerate time-to-market. However, regulatory complexities, supply chain challenges, and the high costs of specialized topical formulations remain significant hurdles. As pharmaceutical firms prioritize efficiency and flexibility, how will CDMOs continue to drive innovation in the topical drug sector?

What Technological Innovations Are Advancing Topical Drug CDMO Capabilities?

Advancements in microencapsulation and nanoparticle-based drug delivery are improving the efficacy and stability of topical formulations. AI-driven predictive modeling is optimizing formulation development, reducing time and costs in early-stage trials. Transdermal microneedle patches are emerging as a non-invasive alternative for drug delivery, expanding CDMO capabilities beyond traditional creams and ointments. Smart manufacturing technologies, including continuous processing and real-time quality control analytics, are enhancing production efficiency. Additionally, biopharmaceutical advancements are allowing the incorporation of peptides and proteins into topical therapies, expanding treatment options for chronic skin diseases and pain management.

Why Is the Demand for Topical Drug CDMOs Increasing?

The rising prevalence of dermatological conditions, increasing preference for non-invasive drug administration, and growing demand for transdermal drug delivery systems are driving the need for specialized CDMOs. Pharmaceutical companies are increasingly outsourcing development and manufacturing to reduce infrastructure costs and navigate stringent regulatory requirements. The emergence of personalized medicine and customized topical therapies is further fueling demand for flexible CDMO partnerships.

What Factors Are Driving the Growth of the Topical Drug CDMO Market?

The market is growing due to advancements in drug delivery technologies, increasing outsourcing of pharmaceutical manufacturing, rising demand for dermatological and transdermal therapies, and expanding CDMO capabilities in biopharmaceutical formulations. As the global pharmaceutical landscape continues to embrace contract manufacturing, CDMOs specializing in topical drugs are poised for significant growth, offering innovative, cost-effective solutions for pharmaceutical companies.

SCOPE OF STUDY:

The report analyzes the Topical Drugs CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products); Service Type (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• AbbVie Contract Manufacturing
• Acino
• Adare Pharma Solutions
• Alcami Corporation
• Ascendia Pharmaceuticals
• Aurobindo Pharma
• Avara Pharmaceutical Services
• Avid Bioservices
• Bora Pharmaceuticals
• Cambrex Corporation
• Catalent, Inc.
• CordenPharma
• DPT Laboratories Ltd.
• Famar
• Jubilant HollisterStier
• Kindeva Drug Delivery
• Lubrizol Life Science
• MedPharm Ltd.
• Patheon (Thermo Fisher Scientific)
• PCI Pharma Services
• Pierre Fabre Group
• Piramal Pharma Solutions

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Topical Drugs CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Demand for Dermatology and Pain Relief Products Fuels Topical Drug Outsourcing
  • Growth in Generic and OTC Formulations Boosts Contract Manufacturing Opportunities
  • Rising Complexity of Topical Formulations Drives Need for Specialized CDMO Expertise
  • Focus on Sustained Release and Permeation-Enhanced Technologies Supports R&D Partnerships
  • Regulatory Pressure on In-House Compliance Drives Pharma to Outsource Topical Pipelines
  • Customization of Creams, Gels, Ointments, and Sprays Supports CDMO Differentiation
  • CDMOs Expanding Value-Added Services Including Packaging and Regulatory Filing
  • Growing Clinical Pipeline in Skin Diseases and Wound Care Accelerates CDMO Demand
  • Preference for Site-Specific Drug Delivery Encourages Innovation in Topical Routes
  • Global Pharma Shift to Virtual Models Enhances CDMO Role in Early-Stage Development
  • Emerging Markets Offer Cost-Effective Scale-Up Capabilities for Topical Drug Projects
  • Increasing Demand for Cleanroom Compliance and GMP Facilities Boosts Strategic CDMO Contracts
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Topical Drugs CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Topical Drugs CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Semi-solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Semi-solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Semi-solid Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Liquid Formulations Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Liquid Formulations Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Liquid Formulations Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Solid Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Transdermal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Transdermal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Transdermal Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Contract Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• JAPAN
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• CHINA
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• EUROPE
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Topical Drugs CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• FRANCE
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• GERMANY
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Topical Drugs CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• INDIA
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Topical Drugs CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Topical Drugs CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
• AFRICA
  • Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030

IV. COMPETITION